Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.77 USD | +2.91% | +1.72% | -21.33% |
21/03 | Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating | MT |
21/03 | Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating | MT |
Business Summary
Number of employees: 168
Managers
Managers | Title | Age | Since |
---|---|---|---|
Bob Ang
CEO | Chief Executive Officer | 49 | 07/19/07 |
Nathan Jorgensen
DFI | Director of Finance/CFO | 47 | 01/20/01 |
Chief Tech/Sci/R&D Officer | 51 | 01/19/01 | |
Eyal Attar
CTO | Chief Tech/Sci/R&D Officer | 53 | 12/22/12 |
Sarah Spencer
IRC | Investor Relations Contact | - | - |
Tania Philipp
HRO | Human Resources Officer | 52 | 01/19/01 |
John C. King
PRN | Corporate Officer/Principal | 49 | 01/20/01 |
General Counsel | 76 | 01/20/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Lubner
BRD | Director/Board Member | 60 | 30/20/30 |
Matt Patterson
CHM | Chairman | 52 | 20/20/20 |
Bob Ang
CEO | Chief Executive Officer | 49 | 07/19/07 |
Bill Lundberg
BRD | Director/Board Member | 60 | 31/19/31 |
Daniella Beckman
BRD | Director/Board Member | 45 | 16/20/16 |
Joshua Resnick
BRD | Director/Board Member | 49 | 01/19/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 68,226,070 | 67,426,408 ( 98.83 %) | 10,299 ( 0.0151 %) | 98.83 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.33% | 121M | |
+12.08% | 42.68B | |
+0.67% | 42.4B | |
+46.56% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- VOR Stock
- Company Vor Biopharma Inc.